Drug Profile
Research programme: nanopolymer-conjugated anticancer drugs - Ocuphire Pharma
Alternative Names: HPMA-docetaxel-folate; HPMA-gemcitabine; Nanopolymer anticancer drugs; RX-21101; RX-21202Latest Information Update: 13 Nov 2020
Price :
$50
*
At a glance
- Originator Rexahn Pharmaceuticals
- Class Drug conjugates; Polymers; Pyrimidine nucleosides; Small molecules; Taxanes
- Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer
Most Recent Events
- 05 Nov 2020 Rexahn Pharmaceuticals has been merged with Ocuphire Pharma to form Ocuphire Pharma
- 28 Jan 2020 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in USA (Parenteral)